Journal
POSTGRADUATE MEDICAL JOURNAL
Volume 98, Issue 1165, Pages 866-870Publisher
OXFORD UNIV PRESS
DOI: 10.1136/postgradmedj-2021-140432
Keywords
clinical pharmacology; adult gastroenterology; oesophageal disease; adult oncology
Categories
Ask authors/readers for more resources
A meta-analysis was conducted to reassess the effects of metformin on esophageal cancer, and the results showed that metformin use was associated with a reduced risk of esophageal cancer. More well-designed studies are still needed to further elaborate on these associations.
Objectives Studies on the association between metformin use and the risk of oesophageal cancer (OC) have generated controversial findings. This updated meta-analysis was conducted to reassess the effects of metformin on OC. Methods A comprehensive search strategy was conducted to select relevant studies from origination to February 2021. Heterogeneity was evaluated through the Q test and I-2 statistics. HRs and 95% CIs were pooled through either random-effect or fixed-effect models. Meta-regression, subgroup analyses, sensitivity analysis and publication bias diagnosis were also performed. Results Seven studies with 5 426 343 subjects were included. Metformin use was associated with reduced risk of OC (HR=0.69, 95% CI 0.54 to 0.87, p<0.001). Sensitivity analysis suggested that the results were relatively stable. Conclusion Metformin is associated with a reduced risk of OC. More well-designed studies are still needed to further elaborate on these associations. PROSPERO registration number CRD42021237127.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available